Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544290 | 0.93 | DNM1 (0.38) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL11938906 | 0.90 | DNM1 (0.46) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3626235 | 0.88 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3619992 | 0.88 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL37785 | 0.88 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL37599 | 0.88 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6029725 | 0.88 | DNM1 (0.50) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL19798086 | 0.84 | FDPS (0.41) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL10068356 | 0.82 | CYP2D6 (0.33) | FDPS | |
| SCHEMBL18560318 | 0.82 | DNM1 (0.41) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988537-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |